As of May, 24 BioSyent Inc. (RX) Analysts See $0.07 EPS

May 16, 2018 - By Vernon Rice

On May, 24 WallStreet anticipated BioSyent Inc. (CVE:RX)’s earnings release, according to Faxor. This year’s EPS analyst estimate is anticipated to be $0.07. That is 16.67 % up compareed to $0.06 EPS for last year. In case of $0.07 EPS V_RX’s profit could reach $1.01 million. Wall Street forecasts -30.00 % negative EPS growth as of May, 24. RX reached $10.11 during the last trading session after $0.06 change.BioSyent Inc. has volume of 264 shares. Since May 17, 2017 RX has 0.00% and is . The stock underperformed the S&P 500 by 11.55%.

BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally.The firm is valued at $146.55 million. The Company’s products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of papillary non-muscle invasive bladder cancer.28.08 is the P/E ratio. The company's products also comprise Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; and endoscopies, proctoscopies, rectoscopies, and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.